Please assess the completion status of the following clinical trial:

Trial Title: Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years old~* Acute Ischemic Stroke on the middle cerebral artery territory~* Treatment with iv tPA in the first 3 hours from symptoms onset~Exclusion Criteria:~* Modified Rankin Scale more or equal to 2~* Infectious, inflammatory, neoplastic or hematologic disease~* Anemia (Hto\<34% or Hb\<10g/dl)~* Previous renal failure~* Previous treatment with oral iron supplement~* Minor stroke (NIHSS less than 4), lacunar or posterior territory~* Alcohol consumption (more than 40mg/Kg)~* Pregnancy~* Participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1. Deferoxamine (Type: ACTIVE_COMPARATOR): Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
- 2. Placebo (Type: PLACEBO_COMPARATOR): Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)

Based on this trial design, predict the completion outcome and termination type (if applicable).